Targets for immunochemotherapy in leishmaniasis

References

• Croft SL, Coombs GH. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol.19(11), 502–508 (2003).
   PubMed Web of Science ®Google Scholar
• Dalton JE, Kaye PM. Immunomodulators: use in combined therapy against leishmaniasis. Expert Rev. Anti Infect. Ther.8(7), 739–742 (2010).
   PubMed Web of Science ®Google Scholar
• den Boer M, Argaw D, Jannin J, Alvar J. Leishmaniasis impact and treatment access. Clin. Microbiol. Infect.17(10), 1471–1477 (2011).
   PubMed Web of Science ®Google Scholar
• Antinori S, Schifanella L, Corbellino M. Leishmaniasis: new insights from an old and neglected disease. Eur. J. Clin. Microbiol. Infect. Dis.31(2), 109–118 (2012).
   PubMed Web of Science ®Google Scholar
• Matlashewski G, Arana B, Kroeger A et al. Visceral leishmaniasis: elimination with existing interventions. Lancet Infect. Dis.11(4), 322–325 (2011).
   PubMed Web of Science ®Google Scholar
• Van Assche T, Deschacht M, da Luz RA, Maes L, Cos P. Leishmania -macrophage interactions: insights into the redox biology. Free Radic. Biol. Med.51(2), 337–351 (2011).
   PubMed Web of Science ®Google Scholar
• Dey R, Khan S, Pahari S, Srivastava N, Jadhav M, Saha B. Functional paradox in host-pathogen interaction dictates the fate of parasites. Future Microbiol.2(4), 425–437 (2007).
   PubMed Web of Science ®Google Scholar
• Bhardwaj S, Srivastava N, Sudan R, Saha B. Leishmania interferes with host cell signaling to devise a survival strategy. J. Biomed. Biotechnol.109189 (2010) (2010).
   PubMedGoogle Scholar
• Laskay T, van Zandbergen G, Solbach W. Neutrophil granulocytes as host cells and transport vehicles for intracellular pathogens: apoptosis as infection-promoting factor. Immunobiology213(3–4), 183–191 (2008).
   PubMed Web of Science ®Google Scholar
• Saha P, Mukhopadhyay D, Chatterjee M. Immunomodulation by chemotherapeutic agents against leishmaniasis. Int. Immunopharmacol.11(11), 1668–1679 (2011).
   PubMed Web of Science ®Google Scholar
• Kulshrestha A, Singh R, Kumar D, Negi NS, Salotra P. Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine. Antimicrob. Agents Chemother.55(6), 2916–2921 (2011).
   PubMed Web of Science ®Google Scholar
• Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J. Infect. Dis.179(6), 1485–1494 (1999).
   PubMed Web of Science ®Google Scholar
• Miranda-Verastegui C, Tulliano G, Gyorkos TW et al. First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl. Trop. Dis.3(7), e491 (2009).
   PubMed Web of Science ®Google Scholar
• Sundar S, Rosenkaimer F, Lesser ML, Murray HW. Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. J. Infect. Dis.171(4), 992–996 (1995).
   PubMed Web of Science ®Google Scholar
• Murray HW, Lu CM, Mauze S et al. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun.70(11), 6284–6293 (2002).
   PubMed Web of Science ®Google Scholar
• Murray HW, Brooks EB, DeVecchio JL, Heinzel FP. Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis. Antimicrob. Agents Chemother.47(8), 2513–2517 (2003).
   PubMed Web of Science ®Google Scholar
• Ghosh M, Pal C, Ray M, Maitra S, Mandal L, Bandyopadhyay S. Dendritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis. J. Immunol.170(11), 5625–5629 (2003).
   PubMed Web of Science ®Google Scholar
• Almeida RP, Brito J, Machado PL et al. Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials. Am. J. Trop. Med. Hyg.73(1), 79–81 (2005).
   PubMed Web of Science ®Google Scholar
• El-On J. Current status and perspectives of the immunotherapy of leishmaniasis. Isr. Med. Assoc. J.11(10), 623–628 (2009).
   PubMed Web of Science ®Google Scholar
• Banerjee A, De M, Ali N. Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation. Antimicrob. Agents Chemother.55(4), 1661–1670 (2011).
   PubMed Web of Science ®Google Scholar
• Sane SA, Shakya N, Gupta S. Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis. Exp. Parasitol.127(2), 376–381 (2011).
   PubMed Web of Science ®Google Scholar
• Shakya N, Sane SA, Gupta S. Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator – picroliv. Parasitol. Res.108(4), 793–800 (2011).
   PubMed Web of Science ®Google Scholar
• Shakya N, Sane SA, Vishwakarma P, Bajpai P, Gupta S. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator – picroliv. Acta. Trop.119(2–3), 188–193 (2011).
   PubMed Web of Science ®Google Scholar
• Sane SA, Shakya N, Haq W, Gupta S. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis. J. Antimicrob. Chemother.65(7), 1448–1454 (2010).
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay D, Das NK, Roy S, Kundu S, Barbhuiya JN, Chatterjee M. Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis. J. Infect. Dis.204(9), 1427–1436 (2011).
   PubMed Web of Science ®Google Scholar
• Ansari NA, Ramesh V, Salotra P. Immune response following miltefosine therapy in a patient with post-kala-azar dermal leishmaniasis. Trans. R. Soc. Trop. Med. Hyg.102(11), 1160–1162 (2008).
   PubMed Web of Science ®Google Scholar
• Awasthi A, Mathur R, Khan A et al. CD40 signaling is impaired in L. major-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response. J. Exp. Med.197(8), 1037–1043 (2003).
   PubMed Web of Science ®Google Scholar
• Raman VS, Bhatia A, Picone A et al. Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J. Immunol.185(3), 1701–1710 (2010).
   PubMed Web of Science ®Google Scholar
• Wadhone P, Maiti M, Agarwal R, Kamat V, Martin S, Saha B. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response. J. Immunol.182(11), 7146–7154 (2009).
   PubMed Web of Science ®Google Scholar
• Yamauchi S, Ito H, Miyajima A. IkappaBeta, a nuclear IkappaB protein, positively regulates the NF-kappaB-mediated expression of proinflammatory cytokines. Proc. Natl Acad. Sci. USA107(26), 11924–11929 (2010).
   PubMed Web of Science ®Google Scholar
• Ukil A, Biswas A, Das T, Das PK. 18 Beta-glycyrrhetinic acid triggers curative Th1 response and nitric oxide up-regulation in experimental visceral leishmaniasis associated with the activation of NF-kappa B. J. Immunol.175(2), 1161–1169 (2005).
   PubMed Web of Science ®Google Scholar
• Mukherjee AK, Gupta G, Bhattacharjee S et al. Amphotericin B regulates the host immune response in visceral leishmaniasis: reciprocal regulation of protein kinase C isoforms. J. Infect.61(2), 173–184 (2010).
   PubMed Web of Science ®Google Scholar
• Cummings HE, Barbi J, Reville P et al. Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis. Proc. Natl Acad. Sci. USA109(4), 1251–1256 (2012).
   PubMed Web of Science ®Google Scholar
• Sen R, Chatterjee M. Plant derived therapeutics for the treatment of leishmaniasis. Phytomedicine18(12), 1056–1069 (2011).
   PubMed Web of Science ®Google Scholar